The drugmaker Teva Pharmaceuticals made history in June by launching the first-ever generic version of a GLP-1 diabetes drug. This revolutionary class of medications, which are also growing increasingly popular as treatments for obesity, has proven astoundingly effective in helping diabetes patients manage their condition.
The availability of Teva's generic for Novo Nordisk's Victoza ensures that more patients will have access to these state-of-the-art therapies -- and at lower cost.
The launch is good for the health of millions of Americans living with type 2 diabetes. It's also a textbook case of how the life sciences industry is supposed to work. Leaps in innovation soon lead to mass-scale availability.
